Dr. Barcenas is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1515 Holcombe Blvd
Houston, TX 77030Phone+1 713-794-5446
Summary
- Associate Professor and Breast Medical Oncologist at MD Anderson Cancer Center in Houston Texas who has a research interest in Survivorship care.
Education & Training
University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2010 - 2013
Medical College of GeorgiaResidency, Internal Medicine, 2006 - 2009
Pontifical Xavierian UniversityClass of 1992
Certifications & Licensure
FL State Medical License 2021 - Present
TN State Medical License 2023 - 2026
AZ State Medical License 2023 - 2025
MS State Medical License 2023 - 2025
OK State Medical License 2020 - 2025
TX State Medical License 2010 - 2025
WA State Medical License 2023 - 2025- American Board of Internal Medicine Medical Oncology
- Join now to see all
Clinical Trials
- Atorvastatin in Treating Patients With Stage IIb-III Triple Negative Breast Cancer Who Did Not Achieve a Pathologic Complete Response After Receiving Neoadjuvant Chemotherapy Start of enrollment: 2019 Jan 14
Roles: Principal Investigator, Contact
- Atorvastatin in Treating Patients With Stage IIb-III Triple Negative Breast Cancer Who Did Not Achieve a Pathologic Complete Response After Receiving Neoadjuvant Chemotherapy Start of enrollment: 2019 Jan 14
Roles: Principal Investigator, Contact
Publications & Presentations
PubMed
- 1 citationsProspective, early longitudinal assessment of lymphedema-related quality of life among patients with locally advanced breast cancer: The foundation for building a pati...Anusha Gandhi, Tianlin Xu, Sarah M DeSnyder, Grace L Smith, Ruitao Lin
Breast. 2023-04-01 - 4 citationsAdaptive group-sequential design with population enrichment in phase 3 randomized controlled trials with two binary co-primary endpoints.Arup Kumar Sinha, Lemuel A. Moyé, Linda B. Piller, Jose-Miguel Yamal, Carlos H. Barcenas
Statistics in Medicine. 2019-09-20 - 129 citationsNeoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline BRCA Pathogenic Variant.Jennifer K. Litton, Marion E. Scoggins, Kenneth R. Hess, Beatriz E. Adrada, Rashmi Krishna Murthy
Journal of Clinical Oncology. 2020-02-10
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
